MRK Stock Recent News
MRK LATEST HEADLINES
Many blue chip stocks pay attractive dividends. The Dow Jones Industrial Average (^DJI 0.25%) is loaded with blue chip stocks.
Merck (MRK) closed at $81.35 in the latest trading session, marking a +2.55% move from the prior day.
I use option collars on struggling stocks like Merck & Co., Inc. to cap downside risk while maintaining upside potential, especially when the technicals look uncertain. My MRK collar trade earlier this year limited losses compared to straight ownership, demonstrating why I favor this strategy for "dog" stocks. Currently, MRK stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a new trade yet.
Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday.
Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Company Participants Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M.
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trusted regulatory process and could sow public distrust in vaccinations and federal health agencies.
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
CNBC's Angelica Peebles reports on news regarding vaccines.